An Eye for an Eye: Lucentis and the New Pharmaceutical Value System

A head- to- head trial of Genentech’s Avastin v. Lucentis raises the stakes in the debate over drug pricing. While previous large comparative trials have focused on a number of different drugs--old against new--the Avastin study is evaluating two brand new cutting edge technologies, one for off-label use. Genentech is not alone in finding this unsettling.

By Ramsey Baghdadi

Genentech Inc. did everything right. The company spent hundreds of millions of dollars and a decade developing the vascular endothelial...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Clinical Trials

More from R&D

  • India Tightens Oversight Of CROs With Mandatory Registration

     
    • By 

    Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

  • Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

     
    • By 

    The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

  • How To Decarbonize Pharma R&D

     

    As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.